Introduction
============

Nasopharyngeal carcinoma (NPC) is a squamous-cell cancer that has a remarkable worldwide ethnic and geographic distribution [@B1], [@B2]. High incidence rates of 20-30 per 100,000 people have been reported in South China, especially in Guangdong Province, and these rates are 100-fold higher than those in Western countries [@B3]. Because of its anatomic location and radiosensitivity, radiotherapy, especially intensity modulated radiotherapy (IMRT), has become the standard treatment for NPC, and recently, the value of targeted therapy is increasingly appreciated [@B4]. Although early-stage NPC can be cured, patients usually present with advanced NPC at primary diagnosis, and 20-30% of patients develop local recurrence and/or distant metastasis [@B5]. The TNM staging system is the gold standard for predicting NPC prognosis; however, this system cannot reflect the biological heterogeneity among tumors. Thus, the identification of reliable biomarkers is highly important for improving prognosis prediction and complementing the existing TNM staging system [@B6], [@B7]. Inflammatory cells and proteins play a critical role in tumor development and may serve as prognostic factors in various cancers. Indeed, correlations between prognosis and several hematological biomarkers, such as the lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and Glasgow prognostic score (GPS), have been identified in a wide range of cancers [@B8]-[@B13]. Furthermore, plasma fibrinogen levels and high-density lipoprotein cholesterol (HDL-C) levels have been reported to have prognostic value in predicting survival in colon cancer and gastric cancer, respectively [@B14]. These markers are more easily available and less expensive to assess than other reported markers. Nevertheless, the prognostic significance of these hematological biomarkers in NPC has not been fully elucidated, and further studies are needed. Accordingly, we conducted a meta-analysis to measure the ability of the abovementioned hematological biomarkers to predict clinical outcomes in NPC.

Methods
=======

Search strategy
---------------

We referred to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement in our analysis [@B15]. A systematic literature search was performed to identify articles published prior to February 2018 in the PubMed, Web of Science, EMBASE and Cochrane library. The search terms were as follows: "hematologic markers", "NLR" ("neutrophil-to-lymphocyte ratio", "neutrophil lymphocyte ratio", "neutrophil to lymphocyte ratio", and "neutrophil-lymphocyte ratio"), "LMR" ("lymphocyte-monocyte ratio", "lymphocyte to monocyte ratio", "lymphocyte monocyte ratio", and "lymphocyte-to-monocyte ratio), "HDL-C" ("high-density lipoprotein cholesterol" and "alpha-Lipoproteins"), "PLR" ("platelet lymphocyte ratio", "platelet to lymphocyte ratio", "platelet-to-lymphocyte ratio", and "platelet-lymphocyte ratio"), "GPS" ("Glasgow Outcome Scale" and "Glasgow prognostic score"), "CRP to ALB" or "C-reactive Protein to Albumin Ratio", "plasma fibrinogen", "prognosis" ("prognosis", "outcome", "survival", and "mortality"), and "NPC" ("Nasopharyngeal Neoplasms" and "Nasopharyngeal Cancer"). In addition, references from the identified publications were also retrieved.

Inclusion and exclusion criteria
--------------------------------

The inclusion criteria: (1) NPC diagnosed based on pathological examination; (2) studies including an evaluation of the prognosis value of at least 1 hematologic biomarker, such as NLR, PLR, LMR, CRP/ALB, GPS, plasma fibrinogen or HDL-C, in NPC; and (3) HRs and 95% CIs or p-values available or possible to calculate.

The exclusion criteria: (1) reviews, letters, laboratory studies and case reports; (2) studies not written in English.

Data extraction and quality assessment
--------------------------------------

The data were extracted from the qualified studies by two investigators (SSY and KZ) independently. The following information was recorded: country, year, author\'s name, sample size, survival outcomes, cut-off value, follow-up, disease stage, HRs, and 95% CIs or p-values of overall survival (OS) and progression-free survival (PFS). If available, we preferentially extracted the HRs from multivariable analyses; otherwise, the HRs were extracted from univariate analyses. The quality of the eligible studies was evaluated by the Newcastle-Ottawa Quality Scale (NOS), which includes the following aspects: selection (four points), outcome assessment (three points) and comparability (two points). Studies with scores ≥6 were considered high quality.

Statistical analyses
--------------------

The impact of the hematological biomarkers on OS and PFS was evaluated by pooled HRs and corresponding 95% CIs, which were directly obtained from the studies or calculated according to the methods presented by Tierney [@B16]. Heterogeneity was measured by Cochrane Q test and the I^2^ statistic. A random-effects model was selected if there was significant heterogeneity (*p*\<0.05 and I²\>50%); otherwise, a fixed-effects model was used. We performed a sensitivity analysis by excluding a study and recalculating the combined HRs. Publication bias was evaluated by Begg\'s funnel plots and Egger\'s tests. The statistical analyses were conducted using RevMan5.3 (Cochrane Collaboration) and *p*\<0.05 was considered statistically significant.

Results
=======

Search results and study characteristics
----------------------------------------

The flow chart of literature retrieval is presented in Figure [1](#F1){ref-type="fig"}. In total, 152 studies were initially retrieved from the electronic databases; of these studies, 53 were duplicates. Thirty-five articles remained after screening the titles or abstracts, and then, 12 articles were excluded due to the lack of adequate data. Thus, 23 studies involving 23,417 patients were included in our meta-analysis; the sample sizes ranged from 108 to 3,237. Except for one study, all studies collected data retrospectively [@B17]. The studies were conducted in Asia and published after 2011. The mean score of NOS is 6.95 with a range from 6 to 8. The characteristics of the eligible studies are displayed in Table [1](#T1){ref-type="table"}.

Correlation between hematologic parameters and survival outcomes
----------------------------------------------------------------

### Impact of NLR on OS and PFS in NPC

The association between NLR and OS was illustrated in 10 studies involving 7,031 NPC patients. In all studies, a high NLR was related to a poor OS with a pooled HR of 1.46 (95% CI=1.30-1.63, *p*\<0.00001). Minimal heterogeneity was observed (I²=9%), as illustrated by the forest plot displayed in Figure [2](#F2){ref-type="fig"}. The cut-off values for NLR ranged from 2.28 to 5.0. In total, there were 2,012 patients from 4 studies in the NLR analysis of PFS. As depicted in Figure [3](#F3){ref-type="fig"}a, an NLR higher than the cut-off was related to a poor PFS (HR=1.67, 95% CI=1.36-2.07, *p*\<0.00001) in NPC without heterogeneity (I²=0%).

### Prognostic effect of elevated PLR on OS

Five studies involving 2,520 participants described the effect of PLR on the NPC prognosis. The combined analysis revealed that a high PLR was related to a poor OS (HR=1.62, 95% CI=1.32-1.98, *p*\<0.00001) without significant heterogeneity (I²=20%) (Figure [2](#F2){ref-type="fig"}).

### Prognostic effect of LMR on OS

Four studies involving 2,863 participants reported the effect of LMR on OS. The combined data showed that a high LMR was related to a favorable OS (HR=0.50, 95% CI: 0.43-0.58, *p*\<0.00001) without heterogeneity (I²=0%) (Figure [2](#F2){ref-type="fig"}).

### Prognostic effect of CRP/ALB on OS

The effect of CRP/ALB on OS was reported in 4 studies involving 5,385 patients. Compared with a low CRP/ALB, a high CRP/ALB was obviously related to a poor OS (HR=1.48, 95% CI: 1.27-1.72, *p*\<0.00001; Figure [2](#F2){ref-type="fig"}) without significant heterogeneity (I²=31%).

### Prognostic effect of GPS on OS

Three studies presenting data regarding the effect of GPS on OS among 1008 patients were found. The pooled analysis indicated that a high GPS was obviously related to a poor OS (HR=2.53, 95% CI: 2.02-3.18, *p*\<0.00001; Figure [2](#F2){ref-type="fig"}), and no heterogeneity (I²=0%) was observed.

### Prognostic effect of HDL-C on OS

Only two studies reported the effects of the HDL-C levels on OS, and the pooled analysis showed that HDL-C was not related to OS (HR=1.22, 95% CI: 0.52-2.86, *p*=0.65; Figure [3](#F3){ref-type="fig"}b).

### Prognostic significance of plasma fibrinogen on OS, DFS and DMFS

The effect of plasma fibrinogen on OS, DFS and DMFS was described in 2 studies, 2 studies, and 3 studies, respectively. The pooled HR value suggested that an elevated level of plasma fibrinogen predicted a poor OS (HR=1.90, 95% CI: 1.46-2.49, *p*\<0.00001, Figure [2](#F2){ref-type="fig"}) and DFS (HR=1.59, 95% CI: 1.32-1.92, *p*\<0.00001, Figure [3](#F3){ref-type="fig"}c) with no heterogeneity (I²=0%); the same effect was found on DMFS (HR=1.96, 95% CI: 1.32-2.91, *p*=0.008) but with significant heterogeneity (I²=79%) (Figure [4](#F4){ref-type="fig"}a).

### Sensitivity analyses

Regarding the pooled HR of the effect of plasma fibrinogen on DMFS, the sensitivity analysis showed that one particular study conducted by Mei Lan et al. [@B18] markedly affected the pooled effects as the combined HR changed from 1.96 (95% CI: 1.32-2.91, *p*=0.008, I²=79%) to 1.59 (95% CI: 1.31-1.94; *p*\<0.00001, I²=0%) when this study was omitted (Figure [4](#F4){ref-type="fig"}b). We also performed the sensitivity analysis by individually omitting other studies, although no single study substantially affected the pooled outcome.

Publication bias
----------------

We used Begg\'s funnel plots and Egger\'s tests to screen for potential publication bias, and no clear publication bias was observed.

Discussion
==========

To date, various markers, including hematological parameters, have been applied for the prediction of tumor outcomes. Increasing evidence reveals that a relationship exists between the systematic inflammatory response and carcinoma, and the association with inflammatory proteins (GPS, plasma fibrinogen and HDL-C) has also been reported. These markers can be inexpensive and are readily available. Thus, we performed this meta-analysis to evaluate the prognostic significance of hematological parameters in NPC.

Our pooled analysis showed that hematological markers, including NLR, PLR, LMR, CRP/ALB, GPS and plasma fibrinogen, are related to NPC survival outcomes in Asian populations. Patients with a high LMR were deemed to have a favorable prognosis, whereas high NLR, PLR, CRP/ALB, GPS and plasma fibrinogen were related to a poor prognosis. In addition, the pooled analysis revealed that HDL-C was not associated with prognosis; however, as only two studies were eligible for our analysis, further studies are required.

Although the exact mechanism between hematological parameters and malignancies has not been reported, this association may be illustrated by tumor-infiltrating immune cells and inflammatory proteins. Lymphocytes play a crucial role in the immunologic antitumor responses by inhibiting tumor cell proliferation and inducing cell death. In fact, tumor-infiltrating lymphocytes (TILs) are related to a good prognosis in various cancers [@B19], [@B20]. Moreover, by inducing apoptosis in tumor cells, the interaction between CD 8+ and CD 4+ T cells is necessary for the antitumor reaction[@B21], [@B22], and increased infiltration of CD8+ T lymphocytes has been reported to improve OS and PFS in NPC[@B23]. Overall, effective immunotherapy for NPC may depend on the ability to generate cytotoxic T lymphocytes (CTLs) that can home to nasopharyngeal tissue and other metastatic sites. Nevertheless, platelets may protect tumor cells from immune elimination, support tumor metastasis [@B24] and mediate tumor cell growth, angiogenesis and dissemination by secreting a variety of growth factors [@B25]-[@B27]. Furthermore, an elevated platelet count is reportedly related to a poor prognosis in cancers [@B28], [@B29]. Moreover, neutrophils, representing another type of inflammatory cells, may contribute to tumor cell growth, angiogenesis and metastasis by producing cytokines and releasing angiogenic factors [@B30]. In addition, macrophages derived from circulating monocytes might accelerate tumor progression and angiogenesis [@B31]. Increasing evidence shows that tumor-associated macrophages (TAMs) are related to worse OS [@B32], and Bingle et al. [@B33] demonstrated that the macrophage density in tumors is related to a poor prognosis. In accordance with the above hypothesis, our study determined that high PLR and NLR values are related to poor OS and PFS, whereas high LMR is associated with a favorable prognosis. CRP, which is an acute-phase response protein, is mainly synthesized by hepatocytes induced by pro-inflammatory cytokines [@B10]. Elevated CRP is related to inflammation accompanied by hypoalbuminemia, which results in dystrophia and further leads to a poor prognosis. The CRP/ALB ratio reveals the relationship between systemic inflammatory responses and malnutrition and has been reported to have a prognostic effect in ovarian cancer [@B34], hepatocellular carcinoma [@B10], pancreatic cancer [@B35], lung cancer [@B36] and esophageal carcinoma [@B37]. In our analysis, we combined 4 studies involving 5,385 patients and found that a high CRP/ALB ratio was a significant predictor of an inferior OS in NPC. GPS is another well-recognized inflammation-based prognostic score demonstrated to be associated with survival in various cancers, such as intrahepatic cholangiocarcinoma and ovarian cancer [@B38]-[@B40]. Consistent with the above results, our study indicated that a high GPS was obviously related to poor OS with a convincing conclusion. Additionally, fibrinogen, which is an acute-phase glycoprotein and an important clotting factor, is converted to insoluble fibrin by thrombin, which affects the inflammatory response. Fibrinogen is a bridging factor promoting endothelial adhesion in target organs [@B41], [@B42]. Fibrinogen has also been proven to be a prognostic marker in several cancers, such as ovarian cancer and hepatocellular carcinoma [@B43]. Furthermore, a nomogram based on fibrinogen was generated to predict its prognostic significance in lung cancer, and high fibrinogen levels were related to a shorter OS [@B44]. In our study, high serum fibrinogen levels were associated with a poor NPC patient prognosis. Moreover, HDL-C, which is a key lipoprotein in cholesterol transport involved in certain signaling pathways important for malignant transformation, may be a carrier of sphingosine 1-phosphate (S1P), which plays an essential role in chemoresistance [@B45], [@B46]. Additionally, Takafumi Tamura et al. reported that a low HDL-C level was related to a poor prognosis in gastric cancer [@B47]. However, we could not conclude that HDL-C is associated with clinical outcomes because only two studies were included. Therefore, additional studies are required.

Inflammation-based prognostic scoring systems considering inflammatory cells (lymphocytes, neutrophils, monocytes and platelets) and proteins (ALB, CRP and HDL-C) are useful because these factors play an important role in the proliferation and metastasis of tumor cells.

There are several highlights in this analysis. First, compared with previous studies based on inflammatory biomarkers in nasopharyngeal carcinoma, such as Li Su et al. [@B48], both inflammatory cells and proteins were considered in our study, and we included a larger sample size. In their study, Li Su et al indicated that lymphocyte counts and NLR may serve as prognostic makers, although only 14 studies involving 11,651 NPC patients were included. Second, our study included more valuable predicative biomarkers. Tomohiro F. Nishijima et al. [@B49] and Liangyou Gu et al. [@B50] demonstrated the prognostic significance of LMR in several malignancies; however, only 3 retrospective studies in these meta-analyses assessed the prognostic value of LMR on NPC. To date, several meta-analyses have indicated that an elevated NLR is a valuable predictive biomarker of a poor prognosis in patients with NPC [@B51], [@B52], and the study performed by Yi Fang et al. also indicated that elevated serum CRP levels were related to a worse prognosis in NPC patients [@B53]. However, these meta-analyses only focused on one biomarker. Third, the biomarkers in our study are inexpensive and easily available. Although the prognostic value of Epstein-Barr virus DNA load and circulating microRNAs in NPC patients has been reported in a meta-analysis [@B54], in contrast to the hematological markers in our study, the detection of the Epstein-Barr virus DNA load and circulating microRNAs is expensive and poorly repeatable. Moreover, both random-effects and fixed-effects models were used in our meta-analysis, providing a more comprehensive understanding of the results. Nonetheless, there are also some limitations. First, except for one study, the eligible studies were all retrospective analyses. Second, because the cut-off values were identified based on various criteria, the cut-off values for the hematological parameters differed among the included studies. Third, the hazard ratios were obtained from univariate analyses if multivariate analyses were not available. Fourth, only articles published in English were included. Moreover, almost all eligible studies were conducted in the Chinese population, and only 2 studies were conducted in Singapore. Thus, the conclusions might be confined to the East Asian population because compared with other parts of the world, there are many more cases and a much higher incidence of NPC in China and Southeast Asia [@B55]. Overall, for a biomarker to be used in the clinic, it should be assessed in a systematic manner, and more clinical data are needed to confirm this conclusion.

Conclusion
==========

This meta-analysis suggests that inflammatory cells (such as neutrophils, monocytes, lymphocytes and platelets) and proteins (such as ALB, CRP and HDL-C) have the capacity to predict survival in cancer, including NPC. As widely available and inexpensive biomarkers, hematological parameters may facilitate prognosis prediction in patients with solid tumors. However, prospective and multicenter studies on larger scales are needed to confirm our findings.
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![**Forest plots of the hematological parameters for OS. Abbreviations:** NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; LMR: lymphocyte-to-monocyte ratio; CRP/ALB: C-reactive protein/albumin ratio; GPS: Glasgow prognostic score; OS: overall survival.](jcav10p2568g002){#F2}

![**Forest plots of NLR for PFS (a)**, **HDL for OS (b), and fibrinogen for DFS (c). Abbreviations:** HNLR: high neutrophil-to-lymphocyte ratio; LNLR: low neutrophil-to-lymphocyte ratio; PFS: progression-free survival; h-HDL: high high-density lipoprotein cholesterol; l-HDL: low high-density lipoprotein cholesterol; H-Fibrinogen: high fibrinogen; L-Fibrinogen: low fibrinogen; DFS: disease-free survival.](jcav10p2568g003){#F3}

![**Forest plots of the pooled analysis of the effects of fibrinogen on DMFS (a) and sensitivity analysis of the effect of fibrinogen on DMFS (b). Abbreviations:** H-Fibrinogen: high fibrinogen; L-Fibrinogen: low fibrinogen; DMFS: distant metastasis-free survival.](jcav10p2568g004){#F4}

###### 

Characteristics of the included studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                       Nos.    Country     Prognostic makers   Cut-off   Study type      No. of patients   HR    Survival outcome   Follow-up (months)/median (range)
  ----------------------------------- ------- ----------- ------------------- --------- --------------- ----------------- ----- ------------------ -----------------------------------
  Cui Chen 2014 [@B56]                7       China       NLR                 5         retrospective   211               U/M   PFS/OS             NA

  PLR                                 150                                                                                                          

  GPS                                 1                                                                                                            

  Jian-Rong He 2012 [@B57]            8       China       NLR                 2.74      retrospective   1410              U/M   PFS/OS             41 (2-60)

  Wei Sun 2016 [@B58]                 8       China       NLR                 2.6       retrospective   251               U/M   PFS/OS             50 (5-84)

  PLR                                 163.4                                                                                                        

  Rou Jiang 2015 [@B59]               7       China       LMR                 2.475     retrospective   672               U/M   OS                 NA

  Rou Jiang 2015 [@B60]               7       China       PLR                 153.64    retrospective   1261              U/M   OS/CSS/\           NA
                                                                                                                                DMFS               

  Ying Jin\                           7       China       NLR                 3.6       retrospective   229               U/M   OS                 NA
  2015 [@B61]                                                                                                                                      

  Jing Li\                            7       China       LMR                 5.22      retrospective   1547              U/M   OS/DFS/\           67.07 (1.41-99.02)
  2013 [@B62]                                                                                                                   DMFS               

  Xiao-Hui Li 2016 [@B63]             6       China       NLR                 2.5       retrospective   388               U/M   DSS                NA

  PLR                                 166                                                                                                          

  LMR                                 2.35                                                                                                         

  GPS                                 1                                                                                                            

  Gui-Nan Lin 2014 [@B64]             7       China       LMR                 5.07      retrospective   256               U/M   OS                 22.6 (5.1-42.3)

  Jian-Pei Li 2016 [@B65]             6       China       NLR                 2.48      retrospective   409               U/M   OS                 NA

  PLR                                 146.2                                                                                                        

  GPS                                 1                                                                                                            

  CRP/ALB                             0.03                                                                                                         

  Xin An 2011 [@B66]                  7       China       NLR                 3.73      retrospective   363               M     DSS/DMFS/LRFS      62 (2-92)

  H. Chang 2013 [@B67]                7       China       NLR                 2.5       retrospective   3237              M     DSS                NA

  Melvin Lee Kiang Chua 2016 [@B68]   8       Singapore   NLR                 3         prospective     393               U/M   OS/DFS/\           NA
                                                                                                                                DMFS               

  Chua 2015 [@B69]                    NA\*    Singapore   NLR                 3         RCT             108               U     DFS/DFMS           27.6 (1.32-47.04)

  Aiying Lu 2017 [@B70]               8       China       NLR                 2.28      retrospective   140               M     PFS/OS             68 (5-77)

  Chang-Juan Tao 2016 [@B71]          7       China       CRP/ALB             0.141     retrospective   719               U/M   OS/DMFS            48 (3-89)

  ShaSha He 2016 [@B72]               7       China       CRP/ALB             0.064     retrospective   2685              U/M   OS                 46.30 (0.07-188.43)

  Yuan Zhang 2017 [@B73]              6       China       CRP/ALB             0.05      retrospective   1572              M     OS/DFS/\           NA
                                                                                                                                DMFS               

  Yan-Yan Liu 2016 [@B74]             6       China       HDL-C               1.295     retrospective   2443              M     OS                 95.2 (51.6-110.6)

  Rou Jiang\                          7       China       HDL-C               0.965     retrospective   807               M     OS                 NA
  2014 [@B75]                                                                                                                                      

  Sha-ShaHeB\                         6       China       Fibrinogen          3.345     retrospective   998               M     OS/DMFS            NA
  2017 [@B76]                                                                                                                                      

  Mei Lan 2016 [@B18]                 7       China       Fibrinogen          4         retrospective   755               M     DSS/DFS\           50 (3-87)
                                                                                                                                /DMFS              

  L-Q Tang 2014 [@B77]                7       China       Fibrinogen          3.34      retrospective   2563              U     OS/DFS/\           NA
                                                                                                                                DMFS               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA\*: Newcastle-Ottawa Quality Scale (NOS) is not suitable for RCT.

**Abbreviations:** HR: hazard ratio; NA: not available; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; LMR: lymphocyte-to-monocyte ratio; CRP/ALB: C-reactive protein/albumin ratio; GPS: Glasgow prognostic score; HDL-C: high-density lipoprotein cholesterol; OS: overall survival; PFS: progression-free survival; PFS: disease-free survival; DMFS: distant metastasis-free survival.
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